Cerecin is a global healthcare company with almost 20 years of innovation and leadership in brain health.
At Cerecin we think differently. We develop novel evidence-based solutions that help people; pharmaceuticals, medical foods, diagnostics, medical devices and e-health products. These solutions target conditions ranging from memory impairment to some of the most devastating neurological diseases.
At Cerecin we think differently. We develop novel evidence-based solutions that help people; pharmaceuticals, medical foods, diagnostics, medical devices and e-health products. These solutions target conditions ranging from memory impairment to some of the most devastating neurological diseases.
Location: United States
Employees: 11-50
Phone: +65 6813 2999
Total raised: $90M
Investors 1
| Date | Name | Website |
| - | Arche Inve... | archeinves... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.10.2021 | - | $40M | - |
| 05.10.2018 | - | $50M | - |
Mentions in press and media 9
| Date | Title | Description |
| 05.03.2026 | Cerecin Announces TEDx Talk by CEO Dr. Charles Stacey is Now Available Online | Titled "The Potential of Fasting and Diet in the Future of Medicine" Highlighting the Potential of Ketones - from Fasting, the Ketogenic diet and Pharmaceuticals - to Address Neurological Disease and Improve Brain Health DENVER, C... |
| 27.08.2025 | Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner | DENVER, Aug. 27, 2025 /PRNewswire/ -- Cerecin, a global biotech company focused on neurometabolism, is proud to announce its partnership with the NIHR HealthTech Research Centre (HRC) in Brain Health, joining a distinguished group of indust... |
| 01.12.2023 | Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders. | Cerecin and IMCB signed a Memorandum of Understanding to collaborate in the areas of neurometabolism, neurodegeneration, metabolic regulators, and brain health and function. SINGAPORE and DENVER, Dec. 1, 2023 /PRNewswire/ -- Cerecin Inc., a... |
| 19.09.2023 | Cerecin strengthens position in neurometabolism with addition to pipeline | Cerecin completes in-licensing of an investigational radiolabelled tracer 18FBHB, CER-022, for development and use in positron emission tomography (PET) studies of ketone body metabolism Company expands ketogenic platform following pilot da... |
| 30.08.2023 | Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023 | Data from the pilot study in infantile spasms showed positive outcomes. The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). The Cerecin team will be accompanied by Pha... |
| 01.07.2023 | Clinical Trial Data of Novel Metabolic Mechanism in Migraine: CER-0001, a Ketogenic Investigational Agent | A poster showcasing data from the RELIEF study of CER-0001 (tricaprilin), being investigated for the preventive treatment of migraine, was presented at the 65th Annual Society Meeting of the American Headache Society Data from the pilot stu... |
| 03.10.2022 | Cerecin Closes Series IIB Financing | Cerecin, a Singapore-based clinical-stage biotechnology company pioneering innovative neurotherapeutics, closed the first tranche of a Series IIB financing round. The round was led by SK Securities and KNT Investment. Led by CEO Dr Charles ... |
| 19.10.2021 | Cerecin Raises $40M in Series II and IIA Financing | Cerecin, Inc., a Denver, CO- Melbourne, Australia- and Singapore-based clinical-stage biotechnology company pioneering innovative neurotherapeutics, raised USD $40m in Series A financing. A Series II investment was initially made by long-te... |
| 05.10.2018 | Cerecin Raises US$50M in Funding | Cerecin, previously Accera, Inc., a Singapore-based brain health-focused pharmaceutical company, raised US$50M in the first close of an investment round. This funding was composed of both equity investment and non-dilutive grants. The round... |